Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
1994-1-12
pubmed:abstractText
The gangliosides of melanoma and other tumours of neuroectodermal origin are suitable targets for immune intervention with tumour vaccines. The optimal vaccines in current use contain ganglioside plus bacillus Calmette-Guérin and induce considerable morbidity. We have screened a variety of new adjuvants in the mouse, and describe one antigen-delivery system, proteosomes, which is especially effective. Highly hydrophobic Neisserial outer membrane proteins (OMP) form multimolecular liposome-like vesicular structures termed proteosomes which can readily incorporate amphiphilic molecules such as GD3 ganglioside. The optimal GD3/proteosome vaccine formulation for induction of GD3 antibodies in the mouse is determined. Interestingly, the use of potent immunological adjuvants in addition to proteosomes augments the IgM and IgG antibody titres against OMP in these vaccines but GD3 antibody titres are unaffected. The application of proteosomes to enhance the immune response to GD3 extends the concept of the proteosome immunopotentiating system from lipopeptides to amphipathic carbohydrate epitopes such as cell-surface gangliosides. The demonstrated safety of meningococcal OMP in humans and the data in mice presented here suggest that proteosome vaccines have potential for augmenting the immunogenicity of amphipathic tumour antigens in humans.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0264-410X
pubmed:author
pubmed:issnType
Print
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1199-204
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:8256501-Adjuvants, Immunologic, pubmed-meshheading:8256501-Animals, pubmed-meshheading:8256501-Antibody Formation, pubmed-meshheading:8256501-Antibody Specificity, pubmed-meshheading:8256501-Bacterial Outer Membrane Proteins, pubmed-meshheading:8256501-Bacterial Vaccines, pubmed-meshheading:8256501-Cytotoxicity, Immunologic, pubmed-meshheading:8256501-Female, pubmed-meshheading:8256501-Gangliosides, pubmed-meshheading:8256501-Hypersensitivity, Delayed, pubmed-meshheading:8256501-Immunization, pubmed-meshheading:8256501-Immunoglobulin M, pubmed-meshheading:8256501-Liposomes, pubmed-meshheading:8256501-Melanoma, pubmed-meshheading:8256501-Mice, pubmed-meshheading:8256501-Mice, Inbred BALB C, pubmed-meshheading:8256501-Mice, Inbred C57BL, pubmed-meshheading:8256501-Neisseria gonorrhoeae, pubmed-meshheading:8256501-Neisseria meningitidis
pubmed:year
1993
pubmed:articleTitle
GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3.
pubmed:affiliation
Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't